Vancouver, British Columbia and Columbus, Ohio, May 6, 2025 — SOLVE FSHD, a venture philanthropy organization committed to accelerating therapies for facioscapulohumeral muscular dystrophy (FSHD), today announced a $3 million investment in Armatus Bio, a biotechnology company developing next-generation vectorized RNAi therapeutics for neuromuscular diseases. The investment will support ARM-201, Armatus Bio’s AAV-delivered microRNA therapy …
Vancouver, BC, March 25, 2025 – SOLVE FSHD, a venture philanthropic organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), is pleased to announce a strategic collaboration with Transcripta Bio, a cutting-edge AI-driven drug discovery company. This collaboration will focus on leveraging Transcripta Bio’s advanced drug screening platform to identify and develop promising therapeutic candidates …
Vancouver, BC, December 5, 2024 – SOLVE FSHD, a venture philanthropy organization dedicated to catalyzing innovation and overcoming barriers to accelerate new therapies for facioscapulohumeral muscular dystrophy (FSHD), is calling on innovators worldwide to compete for the USD$10 million FSHD Bonus Prize, part of the XPRIZE Healthspan Competition launched on November 29, 2023. As part of …
Altay Therapeutics is pleased to announce that the FDA has granted Orphan Drug Designation to DX5057, the first and only oral small molecule DUX4 inhibitor in development for facioscapulohumeral muscular dystrophy (FSHD). FSHD affects ~40,000 people in the U.S. and leads to progressive muscle weakness, disability and loss of independence, yet no therapies are currently …
– EPI-321 is the first investigational therapy designed to silence DUX4 expression via epigenetic modulation – FDA has granted Fast Track, Rare Pediatric Disease, and Orphan Drug Designation for EPI-321 in FSHD SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Epicrispr Biotechnologies, a clinical-stage company pioneering gene-modulating therapies, today announced that the first patient has been dosed in its …
Cambridge, Mass., May 12, 2025 – Epicrispr Biotechnologies, a biotechnology company focused on developing curative therapies, today announced it has been named a Finalist Team in XPRIZE Healthspan FSHD Bonus Prize, earning a $250,000 Milestone Award for its work addressing facioscapulohumeral muscular dystrophy (FSHD), one of the most prevalent forms of muscular dystrophy globally. Epicrispr was one of eight global …